Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study.
Newsome SD, Goldstick L, Robertson DS, Bowen JD, Naismith RT, Townsend B, Figueiredo C, Kletzl H, Giraudon M, Bortolami O, Zecevic D, Giacobino C, Clinch S, Shen YA, Deol-Bhullar G, Bermel RA.
Newsome SD, et al. Among authors: zecevic d.
Ann Clin Transl Neurol. 2024 Oct 26. doi: 10.1002/acn3.52229. Online ahead of print.
Ann Clin Transl Neurol. 2024.
PMID: 39460719
Free article.